S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction

Sven T. Pleger, Andrew Remppis, Beatrix Heidt, Mirko Völkers, J. Kurt Chuprun, Matthew Kuhn, Rui Hai Zhou, Erhe Gao, G. Szabó, Dieter Weichenhan, Oliver J. Müller, Andrea D. Eckhart, Hugo A. Katus, Walter J. Koch, Patrick Most

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Myocardial infarction (MI) represents an enormous clinical challenge as loss of myocardium due to ischemic injury is associated with compromised left ventricular (LV) function often leading to acute cardiac decompensation or chronic heart failure. S100A1 was recently identified as a positive inotropic regulator of myocardial contractility in vitro and in vivo. Here, we explore the strategy of myocardial S100A1 gene therapy either at the time of, or 2 h after, MI to preserve global heart function. Rats underwent cryothermia-induced MI and in vivo intracoronary delivery of adenoviral transgenes (4 × 1010 pfu). Animals received saline (MI), the S100A1 adenovirus (MI/AdS100A1), a control adenovirus (MI/AdGFP), or a sham operation. S100A1 gene delivery preserved global in vivo LV function 1 week after MI. Preservation of LV function was due mainly to S100A1-mediated gain of contractility of the remaining, viable myocardium since contractile parameters and Ca2+ transients of isolated MI/AdS100A1 myocytes were significantly enhanced compared to myocytes isolated from both MI/AdGFP and sham groups. Moreover, S100A1 gene therapy preserved the cardiac β-adrenergic inotropic reserve, which was associated with the attenuation of GRK2 up-regulation. Also, S100A1 overexpression reduced cardiac hypertrophy 1 week post-MI. Overall, our data indicate that S100A1 gene therapy provides a potential novel treatment strategy to maintain contractile performance of the post-MI heart.

Original languageEnglish
Pages (from-to)1120-1129
Number of pages10
JournalMolecular Therapy
Volume12
Issue number6
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Genetic Therapy
Myocardial Infarction
Left Ventricular Function
Adenoviridae
Muscle Cells
Myocardium
Cardiomegaly
Transgenes
Adrenergic Agents
Up-Regulation
Heart Failure
Wounds and Injuries

Keywords

  • Contractile function
  • Gene therapy
  • Myocardial infarction
  • S100A1

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Pleger, S. T., Remppis, A., Heidt, B., Völkers, M., Chuprun, J. K., Kuhn, M., ... Most, P. (2005). S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Molecular Therapy, 12(6), 1120-1129. https://doi.org/10.1016/j.ymthe.2005.08.002

S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. / Pleger, Sven T.; Remppis, Andrew; Heidt, Beatrix; Völkers, Mirko; Chuprun, J. Kurt; Kuhn, Matthew; Zhou, Rui Hai; Gao, Erhe; Szabó, G.; Weichenhan, Dieter; Müller, Oliver J.; Eckhart, Andrea D.; Katus, Hugo A.; Koch, Walter J.; Most, Patrick.

In: Molecular Therapy, Vol. 12, No. 6, 12.2005, p. 1120-1129.

Research output: Contribution to journalArticle

Pleger, ST, Remppis, A, Heidt, B, Völkers, M, Chuprun, JK, Kuhn, M, Zhou, RH, Gao, E, Szabó, G, Weichenhan, D, Müller, OJ, Eckhart, AD, Katus, HA, Koch, WJ & Most, P 2005, 'S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction', Molecular Therapy, vol. 12, no. 6, pp. 1120-1129. https://doi.org/10.1016/j.ymthe.2005.08.002
Pleger ST, Remppis A, Heidt B, Völkers M, Chuprun JK, Kuhn M et al. S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. Molecular Therapy. 2005 Dec;12(6):1120-1129. https://doi.org/10.1016/j.ymthe.2005.08.002
Pleger, Sven T. ; Remppis, Andrew ; Heidt, Beatrix ; Völkers, Mirko ; Chuprun, J. Kurt ; Kuhn, Matthew ; Zhou, Rui Hai ; Gao, Erhe ; Szabó, G. ; Weichenhan, Dieter ; Müller, Oliver J. ; Eckhart, Andrea D. ; Katus, Hugo A. ; Koch, Walter J. ; Most, Patrick. / S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction. In: Molecular Therapy. 2005 ; Vol. 12, No. 6. pp. 1120-1129.
@article{42354f064a9947f6b5ca72d01c07e79a,
title = "S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction",
abstract = "Myocardial infarction (MI) represents an enormous clinical challenge as loss of myocardium due to ischemic injury is associated with compromised left ventricular (LV) function often leading to acute cardiac decompensation or chronic heart failure. S100A1 was recently identified as a positive inotropic regulator of myocardial contractility in vitro and in vivo. Here, we explore the strategy of myocardial S100A1 gene therapy either at the time of, or 2 h after, MI to preserve global heart function. Rats underwent cryothermia-induced MI and in vivo intracoronary delivery of adenoviral transgenes (4 × 1010 pfu). Animals received saline (MI), the S100A1 adenovirus (MI/AdS100A1), a control adenovirus (MI/AdGFP), or a sham operation. S100A1 gene delivery preserved global in vivo LV function 1 week after MI. Preservation of LV function was due mainly to S100A1-mediated gain of contractility of the remaining, viable myocardium since contractile parameters and Ca2+ transients of isolated MI/AdS100A1 myocytes were significantly enhanced compared to myocytes isolated from both MI/AdGFP and sham groups. Moreover, S100A1 gene therapy preserved the cardiac β-adrenergic inotropic reserve, which was associated with the attenuation of GRK2 up-regulation. Also, S100A1 overexpression reduced cardiac hypertrophy 1 week post-MI. Overall, our data indicate that S100A1 gene therapy provides a potential novel treatment strategy to maintain contractile performance of the post-MI heart.",
keywords = "Contractile function, Gene therapy, Myocardial infarction, S100A1",
author = "Pleger, {Sven T.} and Andrew Remppis and Beatrix Heidt and Mirko V{\"o}lkers and Chuprun, {J. Kurt} and Matthew Kuhn and Zhou, {Rui Hai} and Erhe Gao and G. Szab{\'o} and Dieter Weichenhan and M{\"u}ller, {Oliver J.} and Eckhart, {Andrea D.} and Katus, {Hugo A.} and Koch, {Walter J.} and Patrick Most",
year = "2005",
month = "12",
doi = "10.1016/j.ymthe.2005.08.002",
language = "English",
volume = "12",
pages = "1120--1129",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - S100A1 gene therapy preserves in vivo cardiac function after myocardial infarction

AU - Pleger, Sven T.

AU - Remppis, Andrew

AU - Heidt, Beatrix

AU - Völkers, Mirko

AU - Chuprun, J. Kurt

AU - Kuhn, Matthew

AU - Zhou, Rui Hai

AU - Gao, Erhe

AU - Szabó, G.

AU - Weichenhan, Dieter

AU - Müller, Oliver J.

AU - Eckhart, Andrea D.

AU - Katus, Hugo A.

AU - Koch, Walter J.

AU - Most, Patrick

PY - 2005/12

Y1 - 2005/12

N2 - Myocardial infarction (MI) represents an enormous clinical challenge as loss of myocardium due to ischemic injury is associated with compromised left ventricular (LV) function often leading to acute cardiac decompensation or chronic heart failure. S100A1 was recently identified as a positive inotropic regulator of myocardial contractility in vitro and in vivo. Here, we explore the strategy of myocardial S100A1 gene therapy either at the time of, or 2 h after, MI to preserve global heart function. Rats underwent cryothermia-induced MI and in vivo intracoronary delivery of adenoviral transgenes (4 × 1010 pfu). Animals received saline (MI), the S100A1 adenovirus (MI/AdS100A1), a control adenovirus (MI/AdGFP), or a sham operation. S100A1 gene delivery preserved global in vivo LV function 1 week after MI. Preservation of LV function was due mainly to S100A1-mediated gain of contractility of the remaining, viable myocardium since contractile parameters and Ca2+ transients of isolated MI/AdS100A1 myocytes were significantly enhanced compared to myocytes isolated from both MI/AdGFP and sham groups. Moreover, S100A1 gene therapy preserved the cardiac β-adrenergic inotropic reserve, which was associated with the attenuation of GRK2 up-regulation. Also, S100A1 overexpression reduced cardiac hypertrophy 1 week post-MI. Overall, our data indicate that S100A1 gene therapy provides a potential novel treatment strategy to maintain contractile performance of the post-MI heart.

AB - Myocardial infarction (MI) represents an enormous clinical challenge as loss of myocardium due to ischemic injury is associated with compromised left ventricular (LV) function often leading to acute cardiac decompensation or chronic heart failure. S100A1 was recently identified as a positive inotropic regulator of myocardial contractility in vitro and in vivo. Here, we explore the strategy of myocardial S100A1 gene therapy either at the time of, or 2 h after, MI to preserve global heart function. Rats underwent cryothermia-induced MI and in vivo intracoronary delivery of adenoviral transgenes (4 × 1010 pfu). Animals received saline (MI), the S100A1 adenovirus (MI/AdS100A1), a control adenovirus (MI/AdGFP), or a sham operation. S100A1 gene delivery preserved global in vivo LV function 1 week after MI. Preservation of LV function was due mainly to S100A1-mediated gain of contractility of the remaining, viable myocardium since contractile parameters and Ca2+ transients of isolated MI/AdS100A1 myocytes were significantly enhanced compared to myocytes isolated from both MI/AdGFP and sham groups. Moreover, S100A1 gene therapy preserved the cardiac β-adrenergic inotropic reserve, which was associated with the attenuation of GRK2 up-regulation. Also, S100A1 overexpression reduced cardiac hypertrophy 1 week post-MI. Overall, our data indicate that S100A1 gene therapy provides a potential novel treatment strategy to maintain contractile performance of the post-MI heart.

KW - Contractile function

KW - Gene therapy

KW - Myocardial infarction

KW - S100A1

UR - http://www.scopus.com/inward/record.url?scp=28444499677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28444499677&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2005.08.002

DO - 10.1016/j.ymthe.2005.08.002

M3 - Article

C2 - 16168714

AN - SCOPUS:28444499677

VL - 12

SP - 1120

EP - 1129

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 6

ER -